Cogent Biosciences, Inc. (COGT) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Waltham, MA, United States. वर्तमान CEO हैं Andrew R. Robbins.
COGT के पास है IPO तिथि 2018-03-29, 205 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $5.92B.
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. The company's lead product candidate, CGT9486, is a selective tyrosine kinase inhibitor designed to treat systemic mastocytosis and advanced gastrointestinal stromal tumors by targeting specific KIT mutations. Cogent also holds a licensing agreement with Plexxikon Inc. for the development and commercialization of bezuclastinib. Headquartered in Cambridge, Massachusetts, the company was founded in 2014 and rebranded from Unum Therapeutics Inc. to Cogent Biosciences, Inc. in October 2020.
